Literature DB >> 16504930

Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines.

Chi-Un Pae1, Chong-Hyeon Yoon, Tae-Suk Kim, Jung-Jin Kim, Sung-Hwan Park, Chang-Uk Lee, Soo-Jung Lee, Chul Lee, In-Ho Paik.   

Abstract

The alteration of T helper 1 (TH1) and TH2 responses and related cell-mediated immunity has been supposed to be associated with the immunological pathogenesis in the development of schizophrenia. Increasing evidence suggested the alteration of cytokines in accordance with the antipsychotic treatment as well, so that this study aimed at investigating the aberration of TH1 and -2 cytokines before and after antipsychotic treatment in patients with schizophrenia. Thirty-five schizophrenic patients with antipsychotic naïve or free more than 2 months participated in the study. We measured the plasma levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-2 (TH1), and IL-6, IL-10 and IL-13 (TH2) at the time of admission and after an 8-week antipsychotic treatment. The IL-6 (p = 0.001) and -13 (p = 0.004) levels were significantly decreased after antipsychotic treatment than those of before antipsychotic treatment. The total and general PANSS score changes were correlated with the change of IL-6 (r = 0.598, corrected p < 0.05; r = 0.550, corrected p = 0.005, respectively). The baseline IL-6 level was correlated with change of general PANSS score (r = 0.449, corrected p = 0.044), whereas changes of other PANSS scores were not correlated with any other baseline cytokine levels. The baseline total PANSS score was correlated with the baseline levels of IL-13 (r = 0.776, corrected p < 0.005). The baseline total and general PANSS scores were correlated with the baseline levels of IL-6 (r = 0.689, corrected p < 0.005; r = 0.653, corrected p < 0.005). The correlations between the baseline levels of cytokines and the duration of illness and the age at onset were not found. Our study supports that TH-2 arm cytokines may be involved in the improvement of psychopathology and symptomatologies of schizophrenia and that antipsychotic drugs may suppress some TH-2 cytokines in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16504930     DOI: 10.1016/j.intimp.2005.10.004

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  17 in total

1.  Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication.

Authors:  Gwyneth Zai; Daniel J Müller; Jan Volavka; Pal Czobor; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy
Journal:  Psychopharmacology (Berl)       Date:  2006-08-24       Impact factor: 4.530

2.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

3.  Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Peter Buckley; Wesley Seabolt; Andrew Mellor; Brian Kirkpatrick
Journal:  Biol Psychiatry       Date:  2011-06-08       Impact factor: 13.382

4.  A pilot study on immuno-psychiatry in the 22q11.2 deletion syndrome: A role for Th17 cells in psychosis?

Authors:  Elfi Vergaelen; Carmen Schiweck; Kristof Van Steeland; Jacqueline Counotte; Wim Veling; Ann Swillen; Hemmo Drexhage; Stephan Claes
Journal:  Brain Behav Immun       Date:  2018-03-19       Impact factor: 7.217

Review 5.  Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment.

Authors:  Monojit Debnath
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-11       Impact factor: 4.147

6.  Association study of interleukin-4 polymorphisms with paranoid schizophrenia in the Polish population: a critical approach.

Authors:  Anna Fila-Danilow; Krzysztof Kucia; Malgorzata Kowalczyk; Aleksander Owczarek; Monika Paul-Samojedny; Paulina Borkowska; Renata Suchanek; Jan Kowalski
Journal:  Mol Biol Rep       Date:  2012-04-24       Impact factor: 2.316

Review 7.  Neuroimmune pharmacology of neurodegenerative and mental diseases.

Authors:  Feng-Shiun Shie; Yun-Hsiang Chen; Chia-Hsiang Chen; Ing-Kang Ho
Journal:  J Neuroimmune Pharmacol       Date:  2010-09-07       Impact factor: 4.147

8.  Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966.

Authors:  Brian J Miller; Karl-Heinz Herzig; Jari Jokelainen; Toni Karhu; Sirkka Keinänen-Kiukaanniemi; Marjo-Riitta Järvelin; Juha Veijola; Heimo Viinamäki; Erika Jääskeläinen; Matti Isohanni; Markku Timonen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-05-07       Impact factor: 5.270

9.  Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis.

Authors:  Sasi Neelamekam; Milawaty Nurjono; Jimmy Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-12-26       Impact factor: 2.582

10.  Genetic variants in transforming growth factor-β gene (TGFB1) affect susceptibility to schizophrenia.

Authors:  Dorota Frydecka; Blazej Misiak; Jan Aleksander Beszlej; Lidia Karabon; Edyta Pawlak-Adamska; Anna Tomkiewicz; Anna Partyka; Anna Jonkisz; Andrzej Kiejna
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.